<SEC-DOCUMENT>0001096906-25-001708.txt : 20251023
<SEC-HEADER>0001096906-25-001708.hdr.sgml : 20251023
<ACCEPTANCE-DATETIME>20251023150705
ACCESSION NUMBER:		0001096906-25-001708
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251023
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251023
DATE AS OF CHANGE:		20251023

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		251412823

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84070
		BUSINESS PHONE:		8015215301

	MAIL ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20251023_8k.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://utahmed.com/20251023" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D251023" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D251023" id="fact2">false</ix:nonNumeric>
</ix:hidden>
<ix:references>
	<link:schemaRef xlink:type="simple" xlink:href="utmd-20251023.xsd"/>
</ix:references>
<ix:resources>
<i:context id="D251023">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-10-23</i:startDate>
<i:endDate>2025-10-23</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:14pt Times New Roman;margin:0;text-align:center"><b>UNITED STATES </b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center"><b>Washington, D.C. &#160;20549</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b>FORM </b><b><ix:nonNumeric name="dei:DocumentType" contextRef="D251023" escape="true" id="ixv-342">8-K</ix:nonNumeric></b></span></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>CURRENT REPORT</b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;text-align:center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">Date of Report (date of earliest event reported): <b><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D251023" format="ixt:date-monthname-day-year-en" id="ixv-343">October 23, 2025</ix:nonNumeric></b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D251023" escape="true" id="ixv-344">UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D251023" escape="true" id="ixv-345">UT</ix:nonNumeric>AH</b></p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D251023" escape="true" id="ixv-346">000-12575</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D251023" escape="true" id="ixv-347">87-0342734</ix:nonNumeric></b></p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Commission File Number)</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(IRS Employer</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">incorporation or organization)</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">Identification No.)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D251023" escape="true" id="ixv-348">7043 South 300 West</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D251023" escape="true" id="ixv-349">Midvale</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D251023" format="ixt-sec:stateprovnameen" id="ixv-350">Utah</ix:nonNumeric></b></p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D251023" escape="true" id="ixv-351">84047</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices)</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Zip code)</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0">Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>Phone: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="D251023" escape="true" id="ixv-352">801</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D251023" escape="true" id="ixv-353">566-1200</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><b>n/a</b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center">(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="D251023" format="ixt-sec:boolballotbox" id="ixv-354">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="D251023" format="ixt-sec:boolballotbox" id="ixv-355">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="D251023" format="ixt-sec:boolballotbox" id="ixv-356">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="D251023" format="ixt-sec:boolballotbox" id="ixv-357">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D251023" format="ixt-sec:boolballotbox" id="ixv-358">&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:11pt Times New Roman;margin:0"><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt;text-align:justify">Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated October 23, 2025. &#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt;text-align:justify">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:90pt">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0"><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">The following is filed as an exhibit to this report: &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Exhibit</b></p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Number*</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Title of Document</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Location</b></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Item 99.1</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><span style="font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex99z1.htm" style="text-decoration:none">Financial information for Utah Medical Prod</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ucts, Inc. for the three and nine months ended September 30, 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> and forward-loo</a><a href="utmd_ex99z1.htm" style="text-decoration:none">king statements relating to 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> and beyond as present</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ed in a press release dated October 23, 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none">.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">This filing</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">_______________________________________</p>
<p style="font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:-18pt">*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><b>SIGNATURES</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Dated:  October 23, 2025</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">By:</p>
</td><td valign="top" style="width:218.05pt;border-bottom:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:218.05pt;border-top:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND FORWARD-LOOKING STATEMENTS RELATING TO 2025 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED OCTOBER 23, 2025.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><B>UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2025</B></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'>Contact: Brian Koopman (801) 566-1200</KBD><KBD style=margin-left:360pt></KBD>October 23, 2025&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;Utah Medical Products, Inc. [Nasdaq: UTMD] reports third quarter (3Q) and first nine months (9M) of calendar year 2025 financial results that were unusually hampered by global trade uncertainty. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>The following is a summary comparison of 3Q and 9M of calendar 2025 with 3Q and 9M 2024 income statement measures:</P>
<P style='font:11pt Times New Roman;margin:0'> &nbsp;</P>
<TABLE style=border-collapse:collapse;width:354.6pt;margin-left:27.9pt><TR style=height:7.2pt><TD valign=top style=width:130.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>2025 to 2024 Comparison</FONT></P>
</TD><TD valign=top style=width:112.5pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:-1.5pt'>3Q</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:-1.5pt;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(July&#8211;September)</FONT></P>
</TD><TD valign=top style=width:111.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>9M</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(January-September)</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:130.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:112.5pt><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;2%)</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:111.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>( &nbsp;7%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:130.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:112.5pt><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;3%)</P>
</TD><TD valign=top style=width:111.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(11%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:130.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:112.5pt><P align=center style='font:11pt Times New Roman;margin:0'>(22%)</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:111.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(16%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:130.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Income Before Tax (EBT):</P>
</TD><TD valign=top style=width:112.5pt><P align=center style='font:11pt Times New Roman;margin:0'>(21%)</P>
</TD><TD valign=top style=width:111.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(17%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:130.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:112.5pt><P align=center style='font:11pt Times New Roman;margin:0'>(26%)</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:111.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(21%)</P>
</TD></TR>
<TR style=height:12.15pt><TD valign=top style=width:130.5pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:112.5pt><P align=center style='font:11pt Times New Roman;margin:0'>(20%)</P>
</TD><TD valign=top style=width:111.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(13%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s 3Q 2025 financial performance was unusually affected by foreign trade events: i.e., the cancellation or possible delay of &#8220;non-changeable/non-cancellable orders&#8221; by two outside the U.S. (OUS) distributors. &nbsp;Payment terms for these distributors in the past have been full payment prior to shipment of ordered devices in order to eliminate risk of uncollectible receivables. So, non-prepayment as a practical matter canceled or changed the previously agreed upon non-changeable/non-cancellable orders. &nbsp;As a result, UTMD lost $976 in 3Q 2025 shipments and $581 in 3Q 2025 revenues. The lower loss of revenues was due to a EUR 360 cancellation fee invoiced UTMD&#8217;s China distributor for Ireland finished goods, work-in-process and custom raw materials which cannot be used for other customers. &nbsp;However, since it appears that the China distributor&#8217;s silence may leave UTMD holding the bag on inventory produced and/or acquired in good faith to complete the cancelled 2025 annual order, in order to report financial results conservatively, UTMD reserved an additional $395 in 3Q 2025 bad debt expense (G&amp;A expense category) which reduced 3Q 2025 operating income by that amount. Although UTMD has enjoyed supplying its devices to the China distributor for more than two decades, if the cancellation fee is not paid, it is unlikely that there will be a future business relationship.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In quick summary, an unexpected loss of $581 in revenues (which helped reduce Ireland&#8217;s gross profit margin by lower absorption of fixed manufacturing overhead expense), and an additional $395 reduction in operating income (from bad debt reserve) occurred in 3Q 2025.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In total, Worldwide (WW) consolidated sales in 3Q 2025 were $193 lower than in 3Q 2024, and were 2,270 lower in year-to-date (9M) 2025 compared to 9M 2024. Sales to UTMD&#8217;s China distributor noted above were $395 (cancellation fee) in 3Q 2025 compared to $781 in 3Q 2024, and $2,054 in 9M 2025 compared to $2,368 in 9M 2024. &nbsp;The negative sales trend from UTMD&#8217;s previous major OEM customer, PendoTECH, continued in 3Q 2025 but has almost bottomed out. Sales to PendoTECH WW were $96 in </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>3Q 2025 compared to $290 in 3Q 2024, and $360 in 9M 2025 compared to $2,346 in 9M 2024. &nbsp;In other words, sales to those two customers were $580 lower in 3Q 2025 compared to 3Q 2024, and $2,300 lower in 9M 2025 compared to 9M 2024, exceeding the aggregate change in UTMD&#8217;s applicable period revenues.  &nbsp;&nbsp;  </FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Sales invoiced in foreign currencies represented 29% of total WW consolidated 3Q 2025 sales (when expressed in USD) and 30% of 9M 2025 total WW consolidated sales. Constant currency sales, U.S. dollar sales using the same foreign currency exchange (FX) rates as in the prior year&#8217;s same periods, were $114 higher in 3Q 2025 as a result of a stronger EUR and GBP compared to 3Q 2024, and $244 higher for 9M 2025. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Profit margins in 3Q and 9M 2025 compared to 3Q and 9M 2024 follow:</P>
<TABLE style=border-collapse:collapse;width:488.6pt;margin-left:-1.7pt><TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>3Q 2025 </P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(Jul &#8211;&nbsp;Sep)</FONT></P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>3Q 2024</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jul &#8211;&nbsp;Sep)</FONT></P>
</TD><TD valign=top style=width:63.75pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>9M 2025</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Sep)</FONT></P>
</TD><TD valign=top style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'>9M 2024</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Sep)</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>57.1%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>58.0% </P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63.75pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>56.8%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>59.3%</P>
</TD></TR>
<TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (OI/ sales):</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>26.6%</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.4%</P>
</TD><TD valign=top style=width:63.75pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>30.4%</P>
</TD><TD valign=top style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.6%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>EBT Margin (EBT/ sales):</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>33.7%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>41.8%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63.75pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>37.3%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>41.5%</P>
</TD></TR>
<TR><TD valign=top style=width:232.1pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin (NI/ sales):</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>26.8%</P>
</TD><TD valign=top style=width:63.8pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>35.6%</P>
</TD><TD valign=top style=width:63.75pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>29.6%</P>
</TD><TD valign=top style=width:65.15pt><P align=center style='font:11pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>34.6%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>EBT = Income Before Taxes = (Operating Income + Non-Operating Income)</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In 3Q and 9M 2025, UTMD&#8217;s GP Margin (GPM) was reduced by planned higher manufacturing overhead costs with lower absorption as a result of lower sales. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Compared to the prior year, OI Margins in 2025 declined as a result of a lower GPM combined with higher operating expenses and lower sales. &nbsp;Excluding litigation expenses and non-cash amortization expense for the amortization of identifiable intangible assets (IIA) resulting from UTMD&#8217;s 2011 purchase of Femcare, both of which are included in General &amp; Administrative (G&amp;A) expenses, the following table compares consolidated WW Operating Expenses for 3Q 2025 and 9M 2025 with the same periods in 2024:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:126.9pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>WW Operating Expense*</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2025</FONT></P>
</TD><TD valign=top style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2024</FONT></P>
</TD><TD valign=top style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2025</FONT></P>
</TD><TD valign=top style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2024</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:126.9pt><P style='font:11pt Times New Roman;margin:0'>Expense &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;[000 $]</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$2,073</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$1,516</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$5,226</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'>$4,821</P>
</TD></TR>
<TR><TD valign=top style=width:126.9pt><P style='font:11pt Times New Roman;margin:0'>Percent of Revenues</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>21.1%</P>
</TD><TD valign=top style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'>15.2%</P>
</TD><TD valign=top style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'>17.7%</P>
</TD><TD valign=top style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'>15.2%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt'>*Excluding litigation expense and UK IIA amortization expense </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The major difference in the table above was a $395 3Q 2025 charge to UTMD&#8217;s bad debt reserve for cancellation fees invoiced UTMD&#8217;s China distributor for cancelling a noncancellable order in 3Q 2025 for which UTMD had already incurred substantial costs. In addition, a stronger EUR and GBP, converting OUS subsidiary foreign currency operating expenses, added $28 to 3Q 2025 operating expenses and $68 to 9M 2025 operating expenses relative to what those expenses would have been using the 2024 periods&#8217; foreign currency exchange (FX) rates. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:126.9pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Litigation Expense</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2025</FONT></P>
</TD><TD valign=top style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2024</FONT></P>
</TD><TD valign=top style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2025</FONT></P>
</TD><TD valign=top style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2024</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:126.9pt><P style='font:11pt Times New Roman;margin:0'>Expense &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;[000 $]</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 384</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 426</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 983</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'>$1,813</P>
</TD></TR>
<TR><TD valign=top style=width:126.9pt><P style='font:11pt Times New Roman;margin:0'>Percent of Revenues</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>3.9%</P>
</TD><TD valign=top style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'>4.3%</P>
</TD><TD valign=top style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'>3.3%</P>
</TD><TD valign=top style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'>5.7%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:126.9pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>UK IIA Amort Expense</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2025</FONT></P>
</TD><TD valign=top style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2024</FONT></P>
</TD><TD valign=top style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2025</FONT></P>
</TD><TD valign=top style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2024</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:126.9pt><P style='font:11pt Times New Roman;margin:0'>Expense &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;[000 GBP]</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&#163; 397</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&#163; 397</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'>&#163;1,192</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'>&#163;1,192</P>
</TD></TR>
<TR><TD valign=top style=width:126.9pt><P style='font:11pt Times New Roman;margin:0'>Expense &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;[000 &nbsp;$]</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 536</P>
</TD><TD valign=top style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 517</P>
</TD><TD valign=top style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'>$1,568</P>
</TD><TD valign=top style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'>$1,522</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:126.9pt><P style='font:11pt Times New Roman;margin:0'>Percent of Revenues</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'>5.5%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:79.5pt><P align=center style='font:11pt Times New Roman;margin:0'>5.2%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.5pt><P align=center style='font:11pt Times New Roman;margin:0'>5.3%</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:81pt><P align=center style='font:11pt Times New Roman;margin:0'>4.8%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The same GBP IIA amortization expenses in both years&#8217; periods, but a greater dilution in the 2025 periods&#8217; OI Margin due to a stronger GBP and lower revenues.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>EBT in 2025 compared to 2024 was lower because of the lower OI combined with lower Non-operating Income. With lower interest rates on lower cash balances due to share repurchases in 2025, non-operating income was $698 in 3Q 2025 compared to $836 in 3Q 2024, and $2,043 in 9M 2025 compared to $2,524 in 9M 2024. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Net Income margins were further reduced by higher income tax provision rates in 2025 relative to 2024. Earnings Per Share (EPS) in 3Q 2025 were only 20% lower than in 3Q 2024 when Net Income was 26% lower, and only 13% lower in 9M 2025 than in 9M 2024 when Net Income was 21% lower, due to share repurchases. Additional income statement details are provided later in this report. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s September 30, 2025 Balance Sheet was stronger than at the end of 2024 with a higher current ratio, lower total liabilities and higher stockholders&#8217; equity, despite the lower sales and earnings, 9M 2025 cash payments of $3,006 in dividends to stockholders and use of $7,361 to repurchase UTMD shares. The 3Q 2025 ending share price increased $1.50 (+2.4%) from the end of 2024.  &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 3Q 2025 compared to the end of calendar year 2024 and the end of 3Q 2024 follow:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-25</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-24</FONT></P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9-30-24</FONT></P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>1.34420</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1.25209</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>7.4%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.33958</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> 0.3%</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>1.17331</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1.03505</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0;margin-right:13.5pt'> &nbsp;&nbsp;&nbsp;13.4%</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.11429</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> 5.3%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>0.66127</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>0.61834</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>6.9%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.69312</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> (4.6%)</P>
</TD></TR>
<TR><TD valign=top style=width:78.6pt><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:52.8pt><P align=right style='font:11pt Times New Roman;margin:0'>0.71789</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>0.69428</P>
</TD><TD valign=top style='width:67.5pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3.4%</P>
</TD><TD valign=top style='width:58.5pt;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.73987</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:11pt Times New Roman;margin:0'> (3.0%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> -<FONT style='border-bottom:1px solid #000000'>3Q 2025</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total WW UTMD consolidated 3Q 2025 sales were $193 (1.9%) lower than in 3Q 2024. WW constant currency sales were $307 (3.1%) lower. U.S. domestic sales were 3.0% higher (without any FX impact), and outside the U.S. (OUS) sales were 8.5% lower. Without the benefit of a weaker USD in converting foreign currency sales, 3Q 2025 OUS sales were 11.1% lower.  </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 3Q 2025 were $172 higher at $5,859 compared to $5,687 in 3Q 2024 despite the $194 lower domestic sales to PendoTech. &nbsp;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct other device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;direct Filshie device sales&#8221;. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and acquisition history. Domestic direct other device sales, representing 69% of total domestic sales, were $290 (+7.7%) higher in 3Q 2025 than in 3Q 2024. Domestic OEM sales, representing 11% of total domestic sales, were $285 (31.0%) lower, including the offsetting $194 lower PendoTECH OEM sales. Direct Filshie device sales, representing 20% of total domestic sales, were $169 (+16.5%) higher in 3Q 2025 compared to 3Q 2024. About half the increase in domestic Filshie sales was due to a 3Q 2025 price increase which was caused by U.S. tariffs. &nbsp;Filshie devices are manufactured in UTMD&#8217;s Ireland subsidiary and sold &#8220;intercompany&#8221;. &nbsp;Prices on intercompany sales are set by comparable third-party sales, i.e. OUS distributors, in order to satisfy taxing authorities. &nbsp;But intercompany sales are eliminated when UTMD sales are consolidated. &nbsp;Unfortunately, the U.S. government has recently set a 15% tariff on medical device imports from Ireland, which is a &#8220;top-line&#8221; excise tax on intercompany sales to the U.S. from UTMD&#8217;s Ireland subsidiary, which substantially increases consolidated expenses without any impact on sales. With the resulting approximate 50% decline in UTMD&#8217;s U.S. Filshie distributor margin, the Company had to increase its prices to U.S. medical facilities, which undoubtedly will be passed to patients, proving the unfavorable inflationary impact of tariffs on the regular private sector U.S. public. &nbsp;&nbsp;&nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales in 3Q 2025 were 8.5% lower at $3,953 compared to $4,318 in 3Q 2024. The decrease in USD-denominated OUS sales was mitigated as a result of a weaker USD relative to the EUR and GBP, which added $114 to OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies in constant currency terms. FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 3Q 2025 and 3Q 2024 for revenue purposes follow:</P>
<TABLE align=center style=border-collapse:collapse><TR style=height:7.2pt><TD valign=top style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:17.6pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>3<FONT style='border-bottom:1px solid #000000'>Q 2025</FONT></P>
</TD><TD valign=top style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>3<FONT style='border-bottom:1px solid #000000'>Q 2024</FONT></P>
</TD><TD valign=top style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:17.6pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.3485</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.3009</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>+ 3.7%</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:17.6pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.1748</P>
</TD><TD valign=top style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.1091</P>
</TD><TD valign=top style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>+ 5.9%</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:17.6pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.6548</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.6687</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>( &nbsp;2.1%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:17.6pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:58.9pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.7256</P>
</TD><TD valign=top style=width:58.5pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.7339</P>
</TD><TD valign=top style=width:54pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>( &nbsp;1.1%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The weighted average favorable FX rate difference impact on 3Q 2025 foreign currency OUS sales was 4.2%, increasing reported USD sales by $114 relative to the same foreign currency sales in 3Q 2024. &nbsp;In constant currency terms, foreign currency sales in 3Q 2025 were 21.7% lower than in 3Q 2024. The portion of OUS sales invoiced in foreign currencies in USD terms were 28.7% of total consolidated 3Q 2025 sales compared to 34.5% in 3Q 2024. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. Export sales from the U.S. to OUS distributors are invoiced in USD. &nbsp;Direct to end-user foreign currency OUS 3Q 2025 sales in USD terms were 6.7% higher in Ireland, 16.3% lower in Canada, 30.5% lower in France, 18.7% lower in AUS/NZ and 0.1% higher in the UK than in 3Q 2024. Aggregate sales to OUS distributors were $225 (8.3%) lower in 3Q 2025 than in 3Q 2024. This included the two OUS distributors which postponed or cancelled $581 in non-changeable/ noncancellable shipments. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>9M 2025</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 9M 2025 UTMD WW consolidated sales were $2,271 (7.2%) lower than in 9M 2024. Constant currency 9M 2025 sales were helped $244 (+0.8%) due to a generally weaker USD year-to-date. U.S. domestic sales were 2.3% lower and OUS sales were 13.3% lower. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 9M 2025 were $17,308 compared to $17,709 in 9M 2024. &nbsp;Direct other device sales, representing 69% of total domestic sales, were $1,072 (+9.8%) higher in 9M 2025 than in 9M 2024. Domestic OEM sales, representing 11% of total domestic sales, were $1,706 (46.3%) lower. The PendoTECH portion of domestic OEM sales were $1,985 (84.6%) lower. In other words, 9M 2025 non-PendoTECH OEM sales were $279 higher. Direct domestic Filshie device sales, representing 19% of total domestic sales, were $233 (+7.5%) higher in 9M 2025 compared to 9M 2024. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales in 9M 2025 were 13.3% lower at $12,167 compared to $14,036 in 9M 2024. The decrease in 9M 2025 USD-denominated OUS sales was mitigated as a result of a weaker USD relative to the GBP and EUR which added a net $244 to OUS sales (constant currency terms) after the offsetting negative impact of a weaker AUD and CAD. &nbsp;FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 9M 2025 and 9M 2024 for revenue purposes follow:</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=top style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:68.1pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2025</FONT></P>
</TD><TD valign=top style=width:62.4pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2024</FONT></P>
</TD><TD valign=top style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.1pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.3145</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:62.4pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.2760</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>+ 3.0%</P>
</TD></TR>
<TR><TD valign=top style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:68.1pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.1333</P>
</TD><TD valign=top style=width:62.4pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 1.0886</P>
</TD><TD valign=top style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>+ 4.1%</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.1pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.6396</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:62.4pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.6617</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>( &nbsp;3.3%)</P>
</TD></TR>
<TR><TD valign=top style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:36pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:68.1pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.7144</P>
</TD><TD valign=top style=width:62.4pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'> 0.7355</P>
</TD><TD valign=top style=width:63pt;padding-left:5.4pt;padding-right:5.4pt><P style='font:11pt Times New Roman;margin:0'>( &nbsp;2.9%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The weighted-average favorable impact on 9M 2025 WW consolidated sales was 0.8%, increasing reported USD sales by $244 compared to using the same foreign currency exchange rates as in 9M 2024. In constant currency terms, OUS sales in 9M 2025 were 15.1% lower than in 9M 2024. The portion of OUS sales invoiced in foreign currencies in USD terms was 30.0% of total consolidated 9M 2025 sales compared to 33.5% in 9M 2024. Direct to end-user foreign currency OUS 9M 2025 sales in USD terms </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>were 17.2% lower in Ireland, 20.4% lower in Canada, 24.0% lower in France, 4.5% lower in the UK and 20.0% lower in AUS/NZ. Sales to OUS distributors/OEM customers were 13.6% lower in 9M 2025 than in 9M 2024. </FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The 2025 decline in PendoTech OEM sales has been as expected in projections at the beginning of the year (about $2.3 million lower for the year). But with the unexpected distributor cancellations experienced in 3Q 2025 and generally weaker OUS economic conditions, management now expects that total annual 2025 consolidated sales may be about 7% lower compared to 2024, instead of the beginning of year 5% projection. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers from revenues. UTMD&#8217;s GP was $198 (3.4%) lower in 3Q 2025 than in 3Q 2024, and $2,083 (11.1%) lower in 9M 2025 than in 9M 2024. Manufacturing costs include U.S. tariffs on imported components which were $78 in 3Q 2025, mostly due to importing Filshie devices from UTMD Ireland, compared to zero in 3Q 2024. &nbsp;Tariffs in 9M 2025 were $94 compared to $15 in 9M 2024. &nbsp;Those amounts do not include price increases on components purchased from U.S. suppliers due to tariffs that they have to pay. &nbsp;Given the Company&#8217;s strategy of vertical integration in a complex medical device industry, the relatively fixed manufacturing overhead costs of retaining critical management, engineering and quality assurance capabilities dominates the other more variable manufacturing costs of direct labor and materials. &nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. &nbsp;OI in 3Q 2025 was $2,611 compared to $3,343 in 3Q 2024, a 21.9% decline; and was $8,961 in 9M 2025 compared to $10,664 in 9M 2024, a 16.0% decline. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OE are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. The following table summarizes OE in 3Q and 9M 2025 compared to the same periods in 2024 by OE category:</P>
<TABLE style=border-collapse:collapse><TR><TD valign=bottom style=width:59.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OE<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=bottom style=width:54pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>3Q 2025</FONT></P>
</TD><TD valign=bottom style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>3Q 2024</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>9M 2025</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=bottom style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>9M 2024</FONT></P>
</TD><TD valign=bottom style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>$ 516</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;5.3</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 437</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.4</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 1,540</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;5.2</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>$ 1,395</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.4</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>2,310</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>23.5</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1,850</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>18.5</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;5,780</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>19.6</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;6,069</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>19.1</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;167</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.7</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp; 172</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.7</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;457</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;1.6</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp; &nbsp;&nbsp;692</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;2.2</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style=width:54pt><P align=center style='font:11pt Times New Roman;margin:0'>2,993</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>30.5</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>2,459</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>24.6</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> 7,777</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>26.4</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;8,156</P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>25.7</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Changes in foreign currency exchange (FX) rates had a small impact on consolidated financial results in 2025. The FX rate changes are noted in the revenues sections above. A stronger EUR and GBP, offset somewhat by a slightly weaker AUD and CAD in 3Q<FONT style=font-family:Symbol>&#32;</FONT>2025 helped increase OUS S&amp;M expense by $3 and OUS G&amp;A expense by $25, of which $19 was from the same GBP amortization of Femcare IIA in 3Q 2025 and 3Q 2024. A stronger EUR and GBP offset by a weaker AUD and CAD in 9M 2025, increased OUS S&amp;M expenses by $4 and OUS G&amp;A expenses by $64, of which $46 was from the same GBP amortization of Femcare IIA in both 9M 2025 and 9M 2024. There were no OUS R&amp;D expenses. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>S&amp;M expenses in 3Q 2025 were up $79 mainly as a result of increased health plan expenses in the U.S. and higher fees charged by U.S. national distributors. S&amp;M expenses in 9M 2025 were $145 higher for the same reasons, plus as a result of a lower recovery of freight costs to customers. Headcount and salaries did not appreciably increase.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>R&amp;D expenses, only incurred in the U.S., were about the same in 3Q 2025 as in 3Q 2024, but were $235 lower in 9M 2025 compared to 9M 2024 from the completion of independent testing and validation of UTMD&#8217;s own-branded biopharmaceutical high-pressure monitoring devices, which it has begun to market. &nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In conjunction with tables in the overview, a division of G&amp;A expenses by location follows. G&amp;A expenses include non-cash expenses from the amortization of IIA associated with the acquisition of Femcare, as well as litigation expenses:</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:449.6pt><TR style=height:7.2pt><TD valign=top style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A Exp<BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=top style=width:45pt><P align=center style='font:11pt Times New Roman;margin:0'>3Q<BR><FONT style='border-bottom:1px solid #000000'>2025</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:48.35pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>3Q<BR><FONT style='border-bottom:1px solid #000000'>2024</FONT></P>
</TD><TD valign=top style='width:39.25pt;border-right:2.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:49.65pt;border-left:2.25pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>9M<BR><FONT style='border-bottom:1px solid #000000'>2025</FONT></P>
</TD><TD valign=top style='width:39.25pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:49.65pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>9M<BR><FONT style='border-bottom:1px solid #000000'>2024</FONT></P>
</TD><TD valign=top style=width:39.25pt><P align=center style='font:11pt Times New Roman;margin:0'>% of<BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 536</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>5.5</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> $ 517</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;5.2</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$1,568</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>5.3</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$1,522</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'>4.8</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=top style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'>176</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;187</P>
</TD><TD valign=top style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;555</P>
</TD><TD valign=top style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;536</P>
</TD><TD valign=top style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'>U.S. Litigation</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'>389</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>4.0</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;413</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> 4.1</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;977</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>3.3</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,802</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'>5.7</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'>Other&#8211; US:</P>
</TD><TD valign=top style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;667</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp; 582</P>
</TD><TD valign=top style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,864</P>
</TD><TD valign=top style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,740</P>
</TD><TD valign=top style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;96</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;87</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;268</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;273</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>IRE China B/D:</FONT></P>
</TD><TD valign=top style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;395</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4.0</FONT></P>
</TD><TD valign=top style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</P>
</TD><TD valign=top style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>0.0</FONT></P>
</TD><TD valign=top style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;395</P>
</TD><TD valign=top style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1.3</FONT></P>
</TD><TD valign=top style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</P>
</TD><TD valign=top style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>0.0</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;20</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;32</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp; 98</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=top style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;31</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;32</FONT></P>
</TD><TD valign=top style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;100</FONT></P>
</TD><TD valign=top style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp; 98</FONT></P>
</TD><TD valign=top style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:95.4pt><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:45pt><P align=right style='font:11pt Times New Roman;margin:0'>2,310</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:43.8pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>23.5%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:48.35pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,850</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>18.5%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:2.25pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> 5,780</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:39.25pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>19.6%</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.65pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>6,069</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:39.25pt><P align=right style='font:11pt Times New Roman;margin:0'>19.1%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Although the UK IIA amortization expense in GBP was the same as in the prior year&#8217;s same periods, the 3Q 2025 OI margin was diluted by 0.3 percentage points, and the 9M 2025 OI margin was diluted by 0.5 percentage points, due to lower sales and stronger GBP FX rate. The significant Femcare IIA amortization expense, representing more than 5% of current revenues, will end in 1Q 2026 after 15 years. Litigation expenses for Filshie product liability claims in the U.S. were lower in both 3Q and 9M 2025 compared to the same periods in 2024, but still significant at more than 3% of WW revenues. As yet, no case has gone to trial, and a majority of cases have been dismissed.  </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The $460 increase in 3Q 2025 total WW G&amp;A expenses compared to 3Q 2024 was mostly (86%) due to the $395 bad debt provision reserved for cancellation fees charged by UTMD Ireland to its China distributor, resulting in a five-percentage point dilution in UTMD&#8217;s 3Q 2025 OI margin. &nbsp;Despite that unusual 3Q 2025 expense, 9M 2025 G&amp;A expenses were actually $289 lower than in 9M 2024 due to $825 lower litigation expenses in the U.S., but still diluting the 2025 year-to-date OI margin by 0.5 percentage points due to lower sales.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>U.S. G&amp;A expenses other than litigation were $85 higher in 3Q 2025 compared to 3Q 2024, and $124 higher in 9M 2025 compared to 9M 2024. &nbsp;About half of the respective year-over-year increases were due to higher U.S. health plan costs, and the other half to non-cash stock option expense increases. &nbsp;Although G&amp;A headcount remained the same, lower salaries and accrued profit-sharing bonuses offset other increases in outside accounting and other services, director fees and public company administration expenses. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS G&amp;A expenses in USD terms were $1,254 ($1,229 in constant currency) in 3Q 2025 compared to $857 in 3Q 2024. In addition to the $395 bad debt reserve expense in 3Q 2025 which did not occur in 3Q 2024, the total $397 difference was due to $25 impact of FX rate changes from a stronger GBP and EUR. UK IIA amortization expense accounted for $19 of the total $25 increase due to FX rate changes. OUS G&amp;A expenses were $2,940 ($2,876 in constant currency) in 9M 2025 compared to $2,540 in 9M 2024. In addition to the $395 bad debt reserve expense in 9M 2025 which did not occur in 9M 2024, the total $400 difference was due to $64 impact of FX rate changes from a stronger GBP and EUR. UK IIA amortization expense accounted for $46 of the total $64 increase due to FX rate changes.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> </P>
<P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. &nbsp;Consolidated 3Q 2025 EBT was $3,309 (33.7% of sales) compared to $4,179 (41.8% of sales) in 3Q 2024. Consolidated 9M 2025 EBT was $11,004 (37.3% of sales) compared to $13,188 (41.5% of sales) in 9M 2024.  &nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>income and royalties received from licensing the Company&#8217;s technology.  Net NOI in 3Q 2025 was $698 compared to $836 NOI in 3Q 2024. Net NOI in 9M 2025 was $2,042 compared to $2,524 NOI in 9M 2024. UTMD realized a $20 remeasured currency balance loss in 9M 2025 compared to a $3 remeasured currency balance gain in 9M 2024. In 9M 2025, after $10,367 use of cash for dividends and share repurchases, UTMD received $485 less in WW interest income from lower average cash balances and lower interest rates than in 9M 2024. &nbsp;In 9M 2025, UTMD used $7,361 cash for share repurchases compared to $13,259 in 9M 2024. &nbsp;   </FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 3Q 2025 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) of $4,170 was 15.9% lower compared to $4,958 in 3Q 2024. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Adjusted consolidated EBITDA of $13,493 in 9M 2025 was 12.7% lower compared to $15,447 in 9M 2024. Adjusted consolidated EBITDA for the previous four calendar quarters (TTM) was $17,898 as of September 30, 2025. At this point, adjusted consolidated EBITDA for 2025 calendar year as a whole is expected to be in the range of $17 to $18 million.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 42.5% in 3Q 2025 compared to 49.6% in 3Q 2024. &nbsp;UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales was 45.8% in 9M 2025 compared to 48.7% in 9M 2024. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance during a difficult transition period of time. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:</P>
<TABLE style=border-collapse:collapse;width:432pt;margin-left:5.4pt><TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2025</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2024</FONT></P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2025</FONT></P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2024</FONT></P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:207pt><P style='font:11pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$3,309</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$4,179</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$11,004</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$13,188</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>209</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>203</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>614</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>530</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>536</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>517</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,568</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>1,522</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'> 8</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>25</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>26</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>95 </P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>53</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>262 </P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>184</P>
</TD></TR>
<TR><TD valign=top style=width:207pt><P style='font:11pt Times New Roman;margin:0'>Interest Expense</P>
</TD><TD valign=top style=width:49.5pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:58.5pt;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='width:58.5pt;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:58.5pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top bgcolor=#D3F0FE style='width:207pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:49.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> 13</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(2)</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>20</P>
</TD><TD valign=top bgcolor=#D3F0FE style='width:58.5pt;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>(3)</P>
</TD></TR>
<TR><TD valign=top style='width:207pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top style='width:49.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$4,170</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$4,958</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$13,493</P>
</TD><TD valign=top style='width:58.5pt;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$15,447</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>NI in 3Q 2025 of $2,631 (26.8% of sales) was 26.2% lower than NI of $3,563 (35.6% of sales) in 3Q 2024. NI in 9M 2025 of $8,720 (29.6% of sales) was 20.5% lower than NI of $10,972 (34.6% of sales) in 9M 2024. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The average consolidated income tax provisions (as a % of the same period EBT) in 3Q 2025 and 3Q 2024 were 20.5% and 14.7% respectively, and were 20.8% and 16.8% in 9M 2025 and 9M 2024 respectively. The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. Also, periodic true-up adjustments to the provision occur as actual returns are filed by independent accountants. The EBT in UTMD&#8217;s lowest taxed sovereignty, Ireland, was the hardest hit in 3Q and 9M 2025 from the cancellation of OUS distributor orders and lower OUS sales of the Filshie Clip System, both of which are manufactured and sold by UTMD Ireland. The 9M 2025 EBT in the U.S., taxed at a basic corporate rate of 25.5%, was 86% of total 9M 2025 EBT compared to 80% in 9M 2024. &nbsp;In addition, the portion of UTMD&#8217;s NOI generated from interest on high grade tax-exempt municipal bonds was lower in 2025. UTMD has consistently paid millions of dollars in income taxes annually. The basic corporate income tax rates in each of the sovereignties were the same in 2025 as in 2024. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Diluted EPS in 3Q 2025 were $0.820 compared to $1.025 in 3Q 2024, a 19.9% decrease. Diluted shares were 3,207,490 in 3Q 2025 compared to 3,477,797 in 3Q 2024. Diluted EPS in 9M 2025 were $2.680 compared to diluted EPS of $3.098 in 9M 2024, a 13.5% decrease. Diluted shares were 3,254,196 in 9M 2025 compared to 3,541,998 in 9M 2024. The lower diluted shares were the result of share repurchases. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The number of shares used for calculating 3Q 2025 EPS was higher than September 30, 2025 actual outstanding shares because of a time-weighted calculation of average outstanding shares. There was no dilution from unexercised employee and director options. Outstanding shares at the end of 3Q 2025 were 3,204,172 compared to 3,335,156 at the end of calendar year 2024. The difference was due to 130,984 shares repurchased by UTMD in the open market during 9M 2025. &nbsp;There were no option exercises in 9M 2025. For further comparison, actual outstanding shares one year ago at the end of 3Q 2024 were 3,440,525, and at the end of 2023 were 3,629,525. The total number of outstanding unexercised employee and outside director options at September 30, 2025 was 97,511 at an average exercise price of $73.75, including shares awarded but not yet vested. &nbsp;This compares to 73,497 unexercised option shares at the end of 3Q 2024 at an average exercise price of $77.01/ share, including shares awarded but not vested. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Because the average exercise price of employee options was higher than the ending market price of the stock, the number of dilution shares added as a dilution factor for both 3Q 2025 and 9M 2025 was zero. The same was true in 3Q and 9M 2024. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>No employee or director options have been awarded in 2025. Non-qualified option awards of 14,600 shares were made to 47 employees, and an additional 10,000 shares to one new director, in November 2024 at an exercise price of $64.09. UTMD paid $988 ($0.305/share) in dividends to stockholders in 3Q 2025 compared to $1,052 ($0.300/ share) paid in 3Q 2024. <A name=_Hlk179992995 />Dividends paid to stockholders during 3Q 2025 were 38% of 3Q 2025 NI. UTMD paid $3,006 ($0.305/share) in dividends to stockholders in 9M 2025 compared to $3,222 ($0.300/ share) paid in 9M 2024. Dividends paid to stockholders during 9M 2025 were 34% of 9M 2025 NI. <A name=_Hlk211766802 />In 3Q 2025, UTMD purchased 11,729 of its shares for $653, at an average cost of $55.67/ share. Total shares purchased in 9M 2025 were 130,984 for $7,362, at an average cost of $56.20/ share. The shares purchased in 9M 2025 represented 3.9% of shares outstanding at the end of 2024. &nbsp;In comparison, in 3Q 2024, UTMD purchased 58,377 of its shares for $3,866, at an average cost of $66.22/ share. Total shares purchased in 9M 2024 were 196,592 for $13,259, at an average cost of $67.45/ share. The shares purchased in 9M 2024 represented 5.4% of shares outstanding at the end of 2023. Since the end of 2023, when UTMD began to purchase its shares more actively, UTMD has repurchased 432,945 of its shares for $27,329, an average per share cost of $63.12 (representing about 12% of outstanding shares at the end of 2023). In addition, during the same 21- month period of time, UTMD distributed $7,266 in cash dividends to stockholders. In sum, since the end of 2023, UTMD used $34,595 in cash for dividends and share purchases. UTMD&#8217;s cash balance from the end of 2023 to September 30, 2025 has declined just $8,601. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s closing share price at the end of 3Q 2025 was $62.97, up 10.6% from the closing price of $56.92 three months earlier at the end of 2Q 2025, and 2.4% higher than the closing price of $61.47 nine months earlier at the end of 2024. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>At September 30, 2025, UTMD&#8217;s cash and investments increased $1,291 to $84,267 from $82,976 at the end of 2024. &nbsp;The increase resulted despite UTMD using $7,361 of its cash to repurchase 130,984 shares (about 3.9% of 2024-end outstanding shares) in the open market, in addition to paying $3,006 in dividends to stockholders. The $10,367 cash use together with a $1,291 increase in the ending cash balance was provided by UTMD&#8217;s excellent operating 9M 2025 EBITDA of $13,493 (45.8% of revenues). At September 30, 2025, Net Intangible Assets decreased to 12.7% of total consolidated assets from 13.4% on December 31, 2024. UTMD&#8217;s September 30, 2025 current ratio improved because current assets remained the same as at the end of 2024, despite a decline in inventories and receivables, while current liabilities declined 20%. &nbsp;UTMD has no debt. &nbsp;&nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Financial ratios as of September 30, 2025 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 32.1&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 3Q 2025 sales activity) = 34.2&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 3Q 2025 average inventory and CGS) = 2.1&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2025 YTD ROE (before dividends) = 10%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare in general, tax law changes, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC. &nbsp;UTMD&#8217;s 3Q 2025 SEC Form 10-Q will be filed on or before November 14, 2025, and can be accessed on <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B>www.utahmed.com</B></FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B>www.utahmed.com</B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>INCOME STATEMENT, Third Quarter (three months ended September 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<TABLE style=border-collapse:collapse;width:360.9pt><TR style=height:7.2pt><TD valign=top style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2025</FONT></P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3Q 2024</FONT></P>
</TD><TD valign=top style=width:82.65pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 9,812</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$10,005</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:82.65pt><P align=center style='font:10pt Times New Roman;margin:0'>( 1.9%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>5,604</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>5,802</P>
</TD><TD valign=top style=width:82.65pt><P align=center style='font:10pt Times New Roman;margin:0'>( 3.4%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>2,611</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,343</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:82.65pt><P align=center style='font:10pt Times New Roman;margin:0'>(21.9%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>3,309</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>4,179</P>
</TD><TD valign=top style=width:82.65pt><P align=center style='font:10pt Times New Roman;margin:0'>(20.8%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP)</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>2,631</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,564</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:82.65pt><P align=center style='font:10pt Times New Roman;margin:0'>(26.2%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share (US GAAP)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 0.820</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 1.025</P>
</TD><TD valign=top style=width:82.65pt><P align=center style='font:10pt Times New Roman;margin:0'>(19.9%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:140.4pt><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.5pt><P align=right style='font:10pt Times New Roman;margin:0'>3,207</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:70.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,478</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:82.65pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, First Nine Months (nine months ended September 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<TABLE style=border-collapse:collapse;width:356.4pt><TR style=height:7.2pt><TD valign=top style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2025</FONT></P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>9M 2024</FONT></P>
</TD><TD valign=top style=width:76.5pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 29,475</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 31,745</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> ( 7.2%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>16,737</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>18,820</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> (11.1%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>8,961</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>10,664</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> (16.0%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>11,004</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>13,189</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> (16.6%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>Net Income (US GAAP)</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>8,720</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>10,972</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> (20.5%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>EPS (US GAAP)</P>
</TD><TD valign=top style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 2.680</P>
</TD><TD valign=top style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>$ 3.098</P>
</TD><TD valign=top style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'> (13.5%)</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:134.55pt><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:73.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,254</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:72pt><P align=right style='font:10pt Times New Roman;margin:0'>3,542</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:76.5pt><P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse><TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)<BR><FONT style='border-bottom:1px solid #000000'>SEP 30, 2025</FONT></P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)<BR><FONT style='border-bottom:1px solid #000000'>JUN 30, 2025</FONT></P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2024</FONT></P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>SEP 30, 2024</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>$84,267</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$82,179</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>$82,976</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>$88,452</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>3,725</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>3,632</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>4,095</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>3,720</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>8,118</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>8,233</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>8,812</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>9,107</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>422</FONT></P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>331</FONT></P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>448</FONT></P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>377</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>96,532</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>94,375</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>96,331</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>101,656</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>10,000</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>10,257</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>9,762</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>10,419</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>15,443</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,170</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,445</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>17,619</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>$121,975</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$120,802</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>$122,538</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>$129,694</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;768</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;737</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;&nbsp;696</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>$ &nbsp;&nbsp;999</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:18pt'>558 </P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,243</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1,517</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,363</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1,878</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,011</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$2,254</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,757</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'> &nbsp;$3,435</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>248</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>389</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>604</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>779</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability </P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>241</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>256</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>282</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>299</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'>698</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>223</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>370</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>468</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>286</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top bgcolor=#D3F0FE style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>118,252</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,533</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,427</FONT></P>
</TD><TD valign=top bgcolor=#D3F0FE style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>124,197</FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:190.35pt><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:67.65pt><P align=right style='font:10pt Times New Roman;margin:0'>$121,975</P>
</TD><TD valign=top style=width:71.35pt><P align=right style='font:10pt Times New Roman;margin:0'>$120,802</P>
</TD><TD valign=top style=width:68.7pt><P align=right style='font:10pt Times New Roman;margin:0'>$122,538</P>
</TD><TD valign=top style=width:69.95pt><P align=right style='font:10pt Times New Roman;margin:0'>$129,694</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20251023_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20251023"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20251023.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20251023_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20251023"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20251023_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20251023"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20251023.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20251023.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VA70T3N1]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://utahmed.com/20251023' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://utahmed.com/20251023' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2025'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20251023_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20251023_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20251023_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2024-01-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2024-01-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2025/dei-2025.xsd' namespace='http://xbrl.sec.gov/dei/2025'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 23, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Oct. 23,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20251023_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>utmd-20251023.xsd</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20251023_8k.htm">utmd-20251023_8k.htm</File>
    <File>utmd-20251023_def.xml</File>
    <File>utmd-20251023_lab.xml</File>
    <File>utmd-20251023_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20251023_8k.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20251023",
   "dts": {
    "schema": {
     "local": [
      "utmd-20251023.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "inline": {
     "local": [
      "utmd-20251023_8k.htm"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20251023_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20251023_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20251023_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D251023",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20251023_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D251023",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20251023_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20251023/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001096906-25-001708-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-25-001708-xbrl.zip
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M=D5NVS<7'^K=#G35JIO$()<P&Z1DO">=1IV #8$5GJ7CAM^<#9FBQ!&^8CZ
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M==%PCU=]5EX56P#4<["H*47!!ET"L9$!Q"E&GP'O<47*9=,&R\'0-SGZ%]\
MG][#U8WP>H><,R?N3V_":U/$;7]RS=#DO>0BN4JNA.OG:$-J$#*F^_)AYHF^
M:06FKPV\PR"VX1X(R5KQI2I-"$T?P%(-3XB/B>DJG=9)D,^CVIQA/%/Z'AL+
M^(NB:3.)JM4QG>JON@VCX%M</<BGU[A,LJ])^,33V05ESD\ C%!G"&%R?6ZV
MS3<_R\<X@SV&/_>CT.=R\,3Q-4&UVA"T*N4 PI]VR#U0& .MZ_5B^()VDK%.
M^]QCKOYLG^HY!EZ!D$QOZ$^=:&G-S.<$)XT.-1I.R!&V2/J9ITZZ.YZ>IGX
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M5?[-33#*N+$*#P*@!V&M0CTY2U^P4 ]TC18PPO>CB&SJ:,:9@4H6#B,T'46
M$%@^@F 9+Z?Q]'ATYT]O Q^^?DY_BG?Q<;I8I/2L^1(GSNYC%L^S-(1I<2(R
M.AU^_'QUQ,9AFB7A<)[%22IM,Y?^ ]D4@&@G.7J!*M1GN?DG8#,_S=B=#]LQ
M#&#S;^818$.\/X.]3/ ZG-Z%,_H$ED#  3[&L/LC;BJCC_"Y( HG@-,,]C9,
MO^#3\RG:' "#A(<D& 7A5UPCP'H5:PQ7#G0D)Z3-GR4^/(Z&RXF?(=]QU,"4
M  S'VIB#+@@0=^D62'#,YC- _$;(E:@ZP1DY(6ID$&51# @Y&/0\7)FD%(D
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M$7[001.1("K*8V/]E-T5:LH+IS+;X,76V1M.W8#Z -:+"\W%&V%%U*'!6@K
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M $3R,C./9#>!<9C@D+SD*R_YS9^5'01@D))9?2(:@RKEP><I%MKT1]*@>8@
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M0JROA\<2*ELG)Y=L$L"->,1OJV(O4Z']2RL)"!58SH0V%8MVX44(.YWR(F\
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M,#(U,3 R,RYX<V102P$"% ,4    " #A>%=;[V-VH)0.  !_8P  %
M        @ 'Y @  =71M9"TR,#(U,3 R,U\X:RYH=&U02P$"% ,4    " #A
M>%=;J6%?GQ<"   F!P  %0              @ &_$0  =71M9"TR,#(U,3 R
M,U]D968N>&UL4$L! A0#%     @ X7A76U#6'G0>"   TDX  !4
M     ( !"10  '5T;60M,C R-3$P,C-?;&%B+GAM;%!+ 0(4 Q0    ( .%X
M5UL52,KUIP4  $8T   5              "  5H<  !U=&UD+3(P,C4Q,#(S
M7W!R92YX;6Q02P$"% ,4    " #A>%=;N7@YBC5   !LU0$ #P
M    @ $T(@  =71M9%]E>#DY>C$N:'1M4$L%!@     &  8 AP$  )9B
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>utmd-20251023_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20251023.xsd" xlink:type="simple"/>
    <context id="D251023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-10-23</startDate>
            <endDate>2025-10-23</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D251023" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D251023" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D251023" id="ixv-342">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D251023" id="ixv-343">2025-10-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D251023" id="ixv-344">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D251023" id="ixv-345">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D251023" id="ixv-346">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D251023" id="ixv-347">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D251023" id="ixv-348">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D251023" id="ixv-349">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D251023" id="ixv-350">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D251023" id="ixv-351">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D251023" id="ixv-352">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D251023" id="ixv-353">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D251023" id="ixv-354">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D251023" id="ixv-355">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D251023" id="ixv-356">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D251023" id="ixv-357">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D251023" id="ixv-358">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
